FUNDAMENTALS · Fundamentals · KR Healthcare

CLASSYS (214150) Fundamentals 2026 — P/E 20.9x, Revenue Analysis | SniperIQ

CLASSYS (214150) is a KR-listed Healthcare company in Medical - Devices with a market capitalization of ₩2.83T, trading at ₩43400.00 on the KOE. This SniperIQ fundamentals page covers CLASSYS's valuation (P/E 20.9x, P/B 5.4x), profitability (net margin 39.1%), revenue (₩336.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩2.83T
P/E (TTM)20.9x
Net Margin39.1%
Revenue (FY25)₩336.8B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CLASSYS's market cap?

CLASSYS (214150) has a market capitalization of approximately ₩2.83T, trading at ₩43400.00 on the KOE. Market cap moves with the live share price.

What is CLASSYS's P/E ratio?

CLASSYS's trailing twelve-month P/E ratio is 20.9x, with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CLASSYS?

CLASSYS runs a net profit margin of 39.1%, a gross margin of 74.7%, and an operating margin of 48.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CLASSYS generate?

CLASSYS reported revenue of ₩336.8B for fiscal year 2025, with net income of ₩131.9B and earnings per share (EPS) of 2013.57. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CLASSYS pay a dividend?

CLASSYS offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is CLASSYS financially healthy?

CLASSYS carries a debt-to-equity ratio of 0.27x and a current ratio of 1.44x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CLASSYS a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CLASSYS (214150) the key facts are: market cap ₩2.83T, P/E 20.9x, revenue ₩336.8B, 52-week range 40150-77600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track CLASSYS's full fundamentals live

Get CLASSYS's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Medela Potentia (MDLA) fundamentals · D&D Pharmatech (347850) fundamentals · PharmaResearch (214450) fundamentals · SK bioscience (302440) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons